Literature DB >> 18818700

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.

O G Best, A C Gardiner, Z A Davis, I Tracy, R E Ibbotson, A Majid, M J S Dyer, D G Oscier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18818700     DOI： 10.1038/leu.2008.260

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  30 in total

1.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

2.  Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

3.  The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.

Authors:  Douglas E Gladstone; Amanda Blackford; Eunpi Cho; Lode Swinnen; Yvette Kasamon; Christopher D Gocke; Constance A Griffin; Javier Bolaños-Meade; Richard J Jones
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-01-28

Review 4.  The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.

Authors:  Cheng Wang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

5.  On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.

Authors:  D Cortese; L-A Sutton; N Cahill; K E Smedby; C Geisler; R Gunnarsson; G Juliusson; L Mansouri; R Rosenquist
Journal:  Leukemia       Date:  2013-11-12       Impact factor: 11.528

6.  Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

Authors:  Peter Ouillette; Roxane Collins; Sajid Shakhan; Jinghui Li; Edward Peres; Lisa Kujawski; Moshe Talpaz; Mark Kaminski; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

7.  Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Authors:  Nils Winkelmann; Matthew Rose-Zerilli; Jade Forster; Marina Parry; Anton Parker; Anne Gardiner; Zadie Davies; Andrew J Steele; Helen Parker; Nicholas C P Cross; David G Oscier; Jonathan C Strefford
Journal:  Haematologica       Date:  2015-02-20       Impact factor: 9.941

8.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.

Authors:  C Royo; A Navarro; G Clot; I Salaverria; E Giné; P Jares; D Colomer; A Wiestner; W H Wilson; M C Vegliante; V Fernandez; E M Hartmann; N Trim; W N Erber; S H Swerdlow; W Klapper; M J S Dyer; M Vargas-Pabón; G Ott; A Rosenwald; R Siebert; A López-Guillermo; E Campo; S Beà
Journal:  Leukemia       Date:  2012-03-19       Impact factor: 11.528

9.  Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.

Authors:  Paolo Strati; Michael J Keating; Susan M O'Brien; Alessandra Ferrajoli; Jan Burger; Stefan Faderl; Francesco Paolo Tambaro; Nitin Jain; William G Wierda
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

Review 10.  Management of chronic lymphocytic leukemia.

Authors:  Paolo Ghia; Michael Hallek
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.